Table 2.
Efficacy and safety at week 52 n (%)
| Variables | High baseline ALT group | Controls | P value |
| Decrease in HBV DNA level (log10 copies/mL) | 7.03 | 6.17 | < 0.05 |
| HBV DNA negative rate | 29/40 (72.5) | 24/40 (60) | < 0.05 |
| ALT normalization rate | 30/40 (75.0) | 31/40 (77.5) | > 0.05 |
| HBeAg negative rate | 18/40 (45.0) | 11/40 (27.5) | < 0.05 |
| HBeAg seroconversion rate | 15/40 (37.5) | 9/40 (22.5) | < 0.05 |
| HBsAg negative rate | 4/40 (10.0) | 1/40 (2.5) | < 0.05 |
| HBsAg seroconversion rate | 3/40 (7.5) | 0 | < 0.05 |
| Viral breakthrough | 2/40 (5.7) | 3/40 (7.5) | > 0.05 |
| Viral resistance | 1/40 (2.9) | 2/40 (5) | > 0.05 |
| Increased blood creatine kinase | 5/40 (12.5) | 4/40 (10) | > 0.05 |
ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.